Chemoprevention for breast cancer: overcoming barriers to treatment.
Evidence from placebo-controlled, randomized clinical trials supports the use of chemoprevention in women at high risk for developing breast cancer, and two agents-tamoxifen and raloxifene-are U.S. Food and Drug Administration (FDA)-approved for the indication. Despite clinical guidelines that recommend physicians counsel high-risk women about the use of chemoprevention and the estimated 2.4 million women in the United States who meet eligibility criteria for net benefit, the uptake of breast cancer chemoprevention has been exceedingly low. Assessments of the risks and benefits of chemoprevention are aided by the availability of models that can be used to estimate of the risk-benefit ratio. However, many physicians remain unaware of these resources to determine patient eligibility for chemoprevention and lack the time to provide informed counseling to their patients. The barriers for patients' acceptance of chemoprevention treatment include fear of side effects and the perception that chemoprevention will not substantially lower their risk of developing breast cancer. Despite these challenges, there are substantial opportunities to increase the utilization of chemoprevention. These strategies include education, dissemination of user-friendly risk-benefit models, and the support of research efforts focused on identifying biomarkers that can more accurately select women most likely to develop breast cancer and predict responsiveness of treatment.
From the University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Pittsburgh Cancer Institute, Pittsburgh, PA; and National Cancer Institute, Bethesda, MD.
Abenaa M
AM
Brewster
From the University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Pittsburgh Cancer Institute, Pittsburgh, PA; and National Cancer Institute, Bethesda, MD.
Nancy E
NE
Davidson
From the University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Pittsburgh Cancer Institute, Pittsburgh, PA; and National Cancer Institute, Bethesda, MD.
Worta
W
McCaskill-Stevens